Literature DB >> 21523391

Comparison of the binding and internalization properties of 12 DOTA-coupled and ¹¹¹In-labelled CCK2/gastrin receptor binding peptides: a collaborative project under COST Action BM0607.

Luigi Aloj1, Michela Aurilio, Valentina Rinaldi, Laura D'ambrosio, Diego Tesauro, Petra Kolenc Peitl, Theodosia Maina, Rosalba Mansi, Elisabeth von Guggenberg, Lieke Joosten, Jane K Sosabowski, Wouter A P Breeman, Erik De Blois, Stuart Koelewijn, Marleen Melis, Beatrice Waser, Karin Beetschen, Jean Claude Reubi, Marion de Jong.   

Abstract

PURPOSE: Specific overexpression of cholecystokinin 2 (CCK2)/gastrin receptors has been demonstrated in several tumours of neuroendocrine origin. In some of these cancer types, such as medullary thyroid cancer (MTC), a sensitive diagnostic modality is still unavailable and therapeutic options for inoperable lesions are needed. Peptide receptor radionuclide therapy (PRRT) may be a viable therapeutic strategy in the management of these patients. Several CCK2R-targeted radiopharmaceuticals have been described in recent years. As part of the European Union COST Action BM0607 we studied the in vitro and in vivo characteristics of 12 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA)-conjugated CCK2R binding peptides. In the present study, we analysed binding and internalization characteristics. Stability, biodistribution and imaging studies have been performed in parallel by other centres involved in the project.
METHODS: Determination of IC(50) values was performed using autoradiography, with DOTA-peptides displacing (125)I-CCK from receptors on tissue sections from human tumours. Saturation binding and internalization experiments were performed using (111)In-labelled peptides. The rat AR42J cell line and the human A431-CCK2R transfected cell line were utilized for in vitro experiments; dissociation constants (K(d)) and apparent number of binding sites (B(max)) were determined. Internalization was determined in receptor-expressing cells by incubating with tracer amounts of peptide at 37 and 4°C for different times up to 120 min. Surface-bound peptide was then stripped either by acid wash or subsequent incubation with 1 μM unlabelled peptide at 4°C.
RESULTS: All peptides showed high receptor affinity with IC(50) values ranging from 0.2 to 3.4 nM. Saturation experiments also showed high affinity with K(d) values in the 10(-9)-10(-8) M range. B(max) values estimated in A431-CCK2R cells ranged from 0.6 to 2.2 × 10(6) per cell. All peptides showed high levels of internalization when incubated at 37°C.
CONCLUSION: All DOTA-conjugated peptides showed high receptor binding and internalization properties and appear suitable for further characterization, as described in other articles of this issue.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21523391     DOI: 10.1007/s00259-011-1816-y

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN: 1619-7070            Impact factor:   9.236


  24 in total

1.  CCK-2/gastrin receptor-targeted tumor imaging with (99m)Tc-labeled minigastrin analogs.

Authors:  Berthold A Nock; Theodosia Maina; Martin Béhé; Anastasia Nikolopoulou; Martin Gotthardt; Jörg S Schmitt; Thomas M Behr; Helmut R Mäcke
Journal:  J Nucl Med       Date:  2005-10       Impact factor: 10.057

2.  Unsulfated DTPA- and DOTA-CCK analogs as specific high-affinity ligands for CCK-B receptor-expressing human and rat tissues in vitro and in vivo.

Authors:  J C Reubi; B Waser; J C Schaer; U Laederach; J Erion; A Srinivasan; M A Schmidt; J E Bugaj
Journal:  Eur J Nucl Med       Date:  1998-05

3.  Stabilized (111)in-labeled sCCK8 analogues for targeting CCK2-receptor positive tumors: synthesis and evaluation.

Authors:  Susan Roosenburg; Peter Laverman; Lieke Joosten; Annemarie Eek; Wim J G Oyen; Marion de Jong; Floris P J T Rutjes; Floris L van Delft; Otto C Boerman
Journal:  Bioconjug Chem       Date:  2010-04-21       Impact factor: 4.774

4.  Comparison of biological stability and metabolism of CCK2 receptor targeting peptides, a collaborative project under COST BM0607.

Authors:  Meltem Ocak; Anna Helbok; Christine Rangger; Petra Kolenc Peitl; Berthold A Nock; Giancarlo Morelli; Annemarie Eek; Jane K Sosabowski; Wout A P Breeman; Jean Claude Reubi; Clemens Decristoforo
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-04-29       Impact factor: 9.236

5.  Cyclic minigastrin analogues for gastrin receptor scintigraphy with technetium-99m: preclinical evaluation.

Authors:  Elisabeth von Guggenberg; Werner Sallegger; Anna Helbok; Meltem Ocak; Robert King; Stephen J Mather; Clemens Decristoforo
Journal:  J Med Chem       Date:  2009-08-13       Impact factor: 7.446

6.  Improved kinetic stability of DTPA- dGlu as compared with conventional monofunctional DTPA in chelating indium and yttrium: preclinical and initial clinical evaluation of radiometal labelled minigastrin derivatives.

Authors:  Martin Béhé; Wolfgang Becker; Martin Gotthardt; Christa Angerstein; Thomas M Behr
Journal:  Eur J Nucl Med Mol Imaging       Date:  2003-05-24       Impact factor: 9.236

7.  Targeting of CCK-2 receptor-expressing tumors using a radiolabeled divalent gastrin peptide.

Authors:  Jane K Sosabowski; Torkjel Matzow; Julie M Foster; Ciara Finucane; David Ellison; Susan A Watson; Stephen J Mather
Journal:  J Nucl Med       Date:  2009-11-12       Impact factor: 10.057

8.  Targeting of a CCK(2) receptor splice variant with (111)In-labelled cholecystokinin-8 (CCK8) and (111)In-labelled minigastrin.

Authors:  Peter Laverman; Susan Roosenburg; Martin Gotthardt; Jeseong Park; Wim J G Oyen; Marion de Jong; Mark R Hellmich; Floris P J T Rutjes; Floris L van Delft; Otto C Boerman
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-10-13       Impact factor: 9.236

9.  99mTc-labelled HYNIC-minigastrin with reduced kidney uptake for targeting of CCK-2 receptor-positive tumours.

Authors:  E von Guggenberg; H Dietrich; I Skvortsova; M Gabriel; I J Virgolini; C Decristoforo
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-02-17       Impact factor: 10.057

Review 10.  Radiolabeled CCK/gastrin peptides for imaging and therapy of CCK2 receptor-expressing tumors.

Authors:  Susan Roosenburg; Peter Laverman; Floris L van Delft; Otto C Boerman
Journal:  Amino Acids       Date:  2010-03-03       Impact factor: 3.520

View more
  30 in total

1.  Current research in nuclear medicine and molecular imaging: highlights of the 23rd Annual EANM Congress.

Authors:  Ignasi Carrió
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-01-04       Impact factor: 9.236

Review 2.  Radiopharmaceutical development of radiolabelled peptides.

Authors:  Melpomeni Fani; Helmut R Maecke
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-02       Impact factor: 9.236

3.  Gastrin receptor pharmacology.

Authors:  Graham J Dockray; Andy Moore; Andrea Varro; D Mark Pritchard
Journal:  Curr Gastroenterol Rep       Date:  2012-12

4.  NIR-activated content release from plasmon resonant liposomes for probing single-cell responses.

Authors:  Sarah J Leung; Marek Romanowski
Journal:  ACS Nano       Date:  2012-11-07       Impact factor: 15.881

Review 5.  Cholecystokinin-2 Receptor Targeting with Radiolabeled Peptides: Current Status and Future Directions.

Authors:  Maximilian Klingler; Anton Amadeus Hörmann; Elisabeth Von Guggenberg
Journal:  Curr Med Chem       Date:  2020       Impact factor: 4.530

Review 6.  Radiolabelled peptides for oncological diagnosis.

Authors:  Peter Laverman; Jane K Sosabowski; Otto C Boerman; Wim J G Oyen
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-02       Impact factor: 9.236

7.  Evaluation of CCK2 receptor binding ligands: the inheritance of Thomas Behr.

Authors:  Otto C Boerman; Luigi Aloj
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-08       Impact factor: 9.236

8.  177Lu Labeled Cyclic Minigastrin Analogues with Therapeutic Activity in CCK2R Expressing Tumors: Preclinical Evaluation of a Kit Formulation.

Authors:  Christine Rangger; Maximilian Klingler; Lajos Balogh; Zita Pöstényi; Andras Polyak; Dariusz Pawlak; Renata Mikołajczak; Elisabeth von Guggenberg
Journal:  Mol Pharm       Date:  2017-08-07       Impact factor: 4.939

9.  Influence of a novel, versatile bifunctional chelator on theranostic properties of a minigastrin analogue.

Authors:  Joachim Pfister; Dominik Summer; Christine Rangger; Milos Petrik; Elisabeth von Guggenberg; Paolo Minazzi; Giovanni B Giovenzana; Luigi Aloj; Clemens Decristoforo
Journal:  EJNMMI Res       Date:  2015-12-15       Impact factor: 3.138

Review 10.  Receptor binding peptides for target-selective delivery of nanoparticles encapsulated drugs.

Authors:  Antonella Accardo; Luigi Aloj; Michela Aurilio; Giancarlo Morelli; Diego Tesauro
Journal:  Int J Nanomedicine       Date:  2014-03-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.